關於 cookie 的說明

本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗,我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示,便表示您已接受我們的網站使用條款。

搜尋結果Search Result

符合「Biotechnology」新聞搜尋結果, 共 1495 篇 ,以下為 1 - 24 篇 訂閱此列表,掌握最新動態
Valtech Provides Biotechnology and Technology Startup Orientated Valuation Support

HONG KONG, Dec. 7, 2023 /PRNewswire/ -- Valtech Valuation has recently concluded valuations for several projects within the biotechnology and medical technology sector, specifically focusing on genetic engineering. We are honored to have been entrusted with providing valuation opinions to the management of Hong Kong-based and Singapore-based startups seeking private equity investments from international funds. Witnessing the initial success of numerous ambitious Hong Kong startups, Valtech is committed to supporting them throughout their expansion journey. Our company has meticulously crafted a workflow and refined the presentation of valuations for startups to better align with the expectations of investors and founders. The consulting work at Valtech aims to strike a balance, offering the best service for independent price discovery when a startup plans a fundraising campaign or an investor seeks an unbiased evaluation of the founders' asking price. Valtech's approach to startup valuation involves conducting comprehensive research to identify and gather data on comparable deals relevant to the target. This research typically encompasses no fewer than hundreds of potentially relevant private deals and publicly traded companies with valuation metrics pertinent to the target. Max Tsang, Director of Valtech, highlighted, "Companies in the biotechnology industry can be in the pre-clinical phase or different phases of clinical trials with a probability of success or failure. A standard valuation report focuses on discussions of assumptions and three major methodologies: the cost approach, market approach, and income approach. While suitable for financial reporting or independent statutory reporting, a standard valuation report may not suffice. Supplementary materials such as tables, charts, and graphical presentations can enhance the presentation and comprehension of the valuation for a typical startup." As of today, Valtech professionals have contributed to multiple startup projects from HKSTP and Cyberport in Hong Kong, some of which have successfully completed Series A and later funding rounds. We take pride in being trusted valuation advisors who have worked with many fast-growing business stories in Hong Kong. In 2023, Valtech's directors were invited by HKSTP and INNOHK's representatives to deliver a talk to some of their startup members on valuation. Alongside basic concepts and key factors in valuation, Jimmy Wong, another Director of Valtech, shared advanced techniques such as roadmap on valuation, milestone-based market approach, and simulation-based valuations. Valtech has also received commendation from an international pharmaceutical company for its remarkable dedication and delivery of profound valuation insights. Initially founded and based in Hong Kong, Valtech expanded into Singapore in 2023. With a well-designed consulting workflow, proprietary applications, and an ISO 9001 certified quality management system, our consulting team can now serve clients not only in Hong Kong but also in Mainland China, Singapore, and Southeast Asia. Valtech has successfully completed valuation projects for Middle East-based companies and US-listed firms. Valtech's qualified team comprises members with PhDs, CPA (HKICPA), CFA, Chartered Valuation Surveyors of the Royal Institution of Chartered Surveyors, and valuers accredited with Business Valuation (ABV) by AICPA and CVA qualifications in Singapore. Valtech continues to expand into more markets by leveraging its valuation platform and recruiting local experts.

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 278 加入收藏 :
Valtech Provides Biotechnology and Technology Startup Orientated Valuation Support

HONG KONG, Dec. 7, 2023 /PRNewswire/ -- Valtech Valuation has recently concluded valuations for several projects within the biotechnology and medical technology sector, specifically focusing on genetic engineering. We are honored to have been entrusted with providing valuation opinions to the management of Hong Kong-based and Singapore-based startups seeking private equity investments from international funds. Witnessing the initial success of numerous ambitious Hong Kong startups, Valtech is committed to supporting them throughout their expansion journey. Our company has meticulously crafted a workflow and refined the presentation of valuations for startups to better align with the expectations of investors and founders. The consulting work at Valtech aims to strike a balance, offering the best service for independent price discovery when a startup plans a fundraising campaign or an investor seeks an unbiased evaluation of the founders' asking price. Valtech's approach to startup valuation involves conducting comprehensive research to identify and gather data on comparable deals relevant to the target. This research typically encompasses no fewer than hundreds of potentially relevant private deals and publicly traded companies with valuation metrics pertinent to the target. Max Tsang, Director of Valtech, highlighted, "Companies in the biotechnology industry can be in the pre-clinical phase or different phases of clinical trials with a probability of success or failure. A standard valuation report focuses on discussions of assumptions and three major methodologies: the cost approach, market approach, and income approach. While suitable for financial reporting or independent statutory reporting, a standard valuation report may not suffice. Supplementary materials such as tables, charts, and graphical presentations can enhance the presentation and comprehension of the valuation for a typical startup." As of today, Valtech professionals have contributed to multiple startup projects from HKSTP and Cyberport in Hong Kong, some of which have successfully completed Series A and later funding rounds. We take pride in being trusted valuation advisors who have worked with many fast-growing business stories in Hong Kong. In 2023, Valtech's directors were invited by HKSTP and INNOHK's representatives to deliver a talk to some of their startup members on valuation. Alongside basic concepts and key factors in valuation, Jimmy Wong, another Director of Valtech, shared advanced techniques such as roadmap on valuation, milestone-based market approach, and simulation-based valuations. Valtech has also received commendation from an international pharmaceutical company for its remarkable dedication and delivery of profound valuation insights. Initially founded and based in Hong Kong, Valtech expanded into Singapore in 2023. With a well-designed consulting workflow, proprietary applications, and an ISO 9001 certified quality management system, our consulting team can now serve clients not only in Hong Kong but also in Mainland China, Singapore, and Southeast Asia. Valtech has successfully completed valuation projects for Middle East-based companies and US-listed firms. Valtech's qualified team comprises members with PhDs, CPA (HKICPA), CFA, Chartered Valuation Surveyors of the Royal Institution of Chartered Surveyors, and valuers accredited with Business Valuation (ABV) by AICPA and CVA qualifications in Singapore. Valtech continues to expand into more markets by leveraging its valuation platform and recruiting local experts.

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 257 加入收藏 :
L'Oréal-UNESCO For Women in Science 2023 Supports Three Promising Researchers from Singapore in the fields of Material Engineering, Biotechnology, and Sustainable Chemistry

Three promising women researchers emerged as winners out of 42 applicants this year Each winner will receive an endowment worth S$10,000 to advance their research The L'Oréal-UNESCO For Women in Science aims to help bridge the gender gap for women scientists SINGAPORE, Nov. 28, 2023 /PRNewswire/ -- L'Oréal Singapore celebrated three outstanding women researchers in the L'Oréal-UNESCO For Women in Science 2023 program. In an awards ceremony held in Kuala Lumpur on Wednesday, 22nd November 2023, Dr. Leow Wan Ru, Dr. Yang Le, and Dr. Xue Shifeng emerged as the three deserving beneficiaries, each receiving S$10,000 to advance their research. The beneficiaries of the L’Oréal-UNESCO For Women in Science 2022 program (L to R) -Dr. Shifeng Xue, Dr. Leow Wan Ru, Mr Tomas Hruska, Managing Director of L’Oréal Singapore and Dr. Le Yang at the awards ceremony in Kuala Lumpur last week. (Photo credit: L’Oréal Singapore) Dr. Leow is currently a scientist at the Institute of Sustainability for Chemicals, Energy and Environment (ISCE2), researching the use of renewable energy to power chemical reactions. Dr. Yang focuses on the research of PROFESS or Printed Organic Flexible Electronics and Sensors. Her decision to delve into the field of organic and flexible electronics was driven by a deep-seated conviction for innovation and a desire to contribute to a more sustainable and user-centric future. Meanwhile, Dr. Xue's research is centered on the study of epigenetic repression in development and disease, focusing on human congenital disorders. In layman terms, she studies how genes turn on and off, in embryonic development and in disease. Tomas Hruska, Managing Director of L'Oréal Singapore, said "With science as one of our foundational pillars, L'Oréal is dedicated to fostering the potential of girls and women in STEM fields. Our commitment is evident through the L'Oréal-UNESCO For Women in Science program, where we recognize and celebrate outstanding women researchers to help bridge gender gaps. By doing so, we aim to encourage women to pursue their aspirations in science because the world needs science, and science needs women." The L'Oréal-UNESCO Fellowship for Women in Science provides an endowment to help women scientists advance their research – which is in line with the L'Oréal Fondation's three-pronged mission of promoting the progress of inclusive beauty, scientific research, and climate change sustainability. This year marks the 25th global anniversary of the esteemed program. A global initiative by the Fondation L'Oréal, the program was launched in Singapore back in 2009. It has to-date assisted 27 women scientists locally and disbursed over S$270,000 worth of endowment. L'Oréal Singapore partnered with Agency for Science, Technology and Research (A*Star) for this year's program where the esteemed Professor Andy Hor, the Deputy Chief Executive (Research), served as the President Jury. The beneficiaries were selected after stringent assessments by a panel of juries comprising of established researchers such as Professor Andy Hor; Professor Liu Bin, Deputy President (Research and Technology) from National University of Singapore; Professor Lam Yeng Ming, Chair of School of Materials Science and Engineering from Nanyang Technological University Singapore; Professor Archan Misra, Vice Provost (Research) from Singapore Management University; Dr Wan Yue, Deputy Executive Director of Genome Institute of Singapore from A*STAR; Professor Yang Hui Ying from Singapore University of Technology and Design (SUTD); and Associate Professor Low Hong Yee, Head of Pillar, Engineering Product Development (EPD) from SUTD. For more information, please visit - https://www.forwomeninscience.com/.  About L'Oréal Singapore L'Oréal Singapore was established in 1990 and currently has around 20 international brands across luxury, masstige, consumer and hair categories. With more than 900 employees and a Research & Innovation Centre, L'Oréal Singapore is consistently voted as one of the top employers, and was ranked in Universum 2017 as the #1 FMCG Company to Work For. Since 2009, the For Women In Science program is one key program that recognizes talented young women pursuing research in Singapore, while Brandstorm has been leading the field as an innovation incubator for talents and projects since 2001. L'Oréal Singapore is also committed to sustainability, ethics and the community, with multiple initiatives that meet environmental, social and consumer needs. Find out more at https://www.loreal.com/en/singapore/  About L'Oréal Fondation The L'Oréal Fondation embodies the L'Oréal Group's commitment to embracing corporate citizenship through acts of generosity. It focuses on science and beauty – the two pillars on which L'Oréal has built its success for over a century – as the strategic focus for the Foundation's actions. Science stands at the very heart of the Fondation's activities. Its star initiative, the "For Women in Science'' programme developed in partnership with UNESCO, recognizes women who have contributed to scientific progress on every continent, and promotes scientific advances worldwide. The Fondation's other commitments focus on the belief that beauty should be accessible to everyone and that it plays a key role in moving our society forward – through transforming lives through reconstructive surgery, socio-aesthetic workshops or education – as a means of improving the life quality of vulnerable people, helping them return to normal life, and restoring the self-esteem and dignity they need to make their way in society. About UNESCO Since its creation in 1945, UNESCO has pursued its mission of promoting science at the service of sustainable development and peace. It focuses on policy development and building capacities in science, technology and innovation and promoting and strengthening science education and engineering. UNESCO fosters the sustainable management of freshwater, oceans and terrestrial resources, the protection of biodiversity, and using the power of science to cope with climate change and natural hazards. The Organization also works to eliminate all forms of discrimination and to promote equality between men and women, especially in scientific research.  

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 558 加入收藏 :
Biotechnology Start-Up Psylo Wins Hello Tomorrow APAC Deep Tech Competition in Singapore

SINGAPORE, Oct. 31, 2023 /PRNewswire/ -- Psylo, a biotechnology start-up pioneering the development of next-generation serotonergic agents for the treatment of central nervous system (CNS) disorders, today announced that it won the Hello Tomorrow APAC deep tech competition held in Singapore. The Hello Tomorrow APAC Challenge is a prestigious annual competition where deep tech startups from the Asia-Pacific region exhibit their innovative solutions, rooted in advanced science and engineering, to address global challenges. Psylo was selected as the winner from over 200 contenders, securing an equity-free grant and sponsored trips to Singapore and Paris to participate in SLINGSHOT 2023 and the Hello Tomorrow Global challenges, respectively. Leveraging its proprietary platform, Psylo is at the forefront of developing serotonergic agents with enhanced selectivity and efficacy. Their lead 100X series, a class of functionally selective 5-HT2A agonists, has shown promising antidepressant and neuroplasticity-promoting effects in preclinical studies. "We are immensely honoured to have been selected as the winner of the Hello Tomorrow APAC Challenge," said Dr William Jorgensen, Psylo's Director of Medicinal Chemistry and representative at the competition. "This recognition reflects the tireless efforts of our team and the transformative potential of our platform in revolutionising the treatment of CNS disorders." Psylo's Growing Presence in Asia Psylo, headquartered in Australia with operations in the US, is now expanding its presence in Asia. This strategic growth is underscored by a recent sponsored research agreement with Daiichi Sankyo, one of the largest pharmaceutical companies in Japan and world leader in drug development. Under the terms of the agreement, Psylo will receive funding and support for developing psychiatric therapies based on its proprietary platform. "We are eager to expand our presence in Asia," said Joshua Ismin, Psylo's Chief Executive Officer. "Earlier this year we began building a team in the US to support our partnership with Daiichi Sankyo. This win at the Hello Tomorrow APAC Challenge further validates our global strategy." Psylo's Research Progress Psylo is currently advancing four lead series of serotonergic agents with reduced side effects and optimised pharmacological profiles. The 100X series is the most advanced series showing substantial promise for clinical translation. "The 100X series could represent a paradigm shift in psychiatry. This novel class of 5-HT2A agonists, which has shown promising antidepressant effects in preclinical studies and promotion of neuroplasticity, could redefine the treatment of depression and other CNS disorders," said Dr. Samuel Banister, Psylo's Chief Scientific Officer. "Aligned with Psylo's mission, our innovative approach aims to offer a safer and more effective alternative to traditional SSRI antidepressants and reduce suffering from neuropsychiatric and CNS disorders." Psylo is planning to initiate the Investigational New Drug (IND)-enabling studies necessary for human clinical trials in early 2024. About Psylo Psylo is an Australian biotechnology start-up developing next-generation serotonergic agents for the treatment of central nervous system (CNS) disorders. The company's proprietary platform enables the discovery and development of serotonergic agents with improved selectivity and efficacy. Psylo is led by a team of experienced scientists and entrepreneurs with a proven track record in the pharmaceutical industry. Links Hello Tomorrow APAC Challenge: https://www.hello-tomorrow-apac.org/ Psylo announcement of sponsored research agreement with Daiichi Sankyo: https://www.prnewswire.com/news-releases/psylo-announces-sponsored-research-agreement-with-daiichi-sankyo-to-develop-non-hallucinogenic-psychiatric-therapies-301857884.html

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 1151 加入收藏 :
Recbio signed a strategic cooperation agreement with Zimbabwe National Biotechnology Administration and ICGEB China Regional Research Centre

TAIZHOU, China, Oct. 10, 2023 /PRNewswire/ -- On October 8, 2023, Dr. Deckster Tonny SAVADYE, CEO of Zimbabwe NBA, and Dr. Yang Yili, International Centre for Genetic Engineering and Biotechnology China Regional Research Centre(ICGEB), visited Recbio. Dr. SAVADYE and his team conducted an on-the-spot investigation of the manufacturing facilities for the COVID-19/Shingles vaccine and HPV vaccine at Recbio. Witnessed by the leaders of Taizhou Pharmaceutical High-tech Industrial Park, the three parties jointly signed a strategic cooperation agreement. According to the agreement, Recbio will cooperate with ICGEB China Regional Research Center to provide technical support related to vaccine production in Zimbabwe, including personnel training, plant designing, clinical trials, sub-packaging technology, and stock solution technology transfer, etc., with COVID-19 vaccine as the entry point, and gradually expand to other vaccine varieties, contributing to localized vaccine production in Zimbabwe and Africa. The signing of this contract marks that Recbio vaccine D&G and production technology platform and products have been recognized by more international organizations and countries. Recbio will actively implement the national "Belt and Road Initiative" and seize the overseas market layout of vaccines. The Zimbabwe National Biotechnology Authority is a government agency established by legislation in 2006 to promote the application of traditional and cutting-edge biotechnology in the fields of medicine, agriculture, and others. The International Centre for Genetic Engineering and Biotechnology (ICGEB) is an intergovernmental international scientific and technological organization founded in 1983 with the support of the United Nations Industrial Development Organization (UNIDO). Up to now, it has established interactive networks with more than 65 member States and has made outstanding achievements in scientific research, training, and technology transfer to industry. About Recbio Founded in 2012, Jiangsu Recbio Technology Co., Ltd. (hereinafter referred to as Recbio or the Company; stock code: 02179.HK) is an innovative vaccine company driven by self-developed technologies. We are dedicated to the R&D, production and commercialization of innovative vaccines, leveraging our core technology platforms (novel adjuvant, protein engineering, immunological evaluation). Staying true to the mission of "Protect human health with best-in-class vaccines", the Company has established high-value pipelines consisting of several blockbuster vaccines with proprietary rights to satisfy the huge unmet demands in the markets of high-burden diseases.                                                    Through years of devotion to the vaccine industry, Recbio has developed three advanced innovative technology platforms, namely novel adjuvant, protein engineering and immunological evaluation platforms, and become one of the few companies in the world capable of developing novel adjuvant systems. We develop promising vaccine candidates constantly, taking advantage of the synergy between the novel adjuvant platform, optimized antigen designs, and immunological evaluation technologies. Recbio never ceases to optimize its technology platforms, and strives to achieve breakthroughs in mRNA vaccines using a joint venture model.                                                           With robust R&D capacity, the Company has developed high-value innovative vaccine portfolios consisting of ten-odd differentiated vaccines, covering cervical cancer, shingles, COVID-19, TB and other high-burden diseases. Our core product REC603, a recombinant 9-valent HPV vaccine in Phase III clinical trial, shows great promise of becoming the first marketed domestic 9-valent HPV vaccine. Apart from that, ReCOV, a recombinant COVID-19 vaccine with its commercialization in the offing, has been recognized as one of the most competitive next-generation COVID-19 vaccines in the world. Recbio has a clear commercialization strategy aiming to penetrate the diversified global vaccine market. Honed and refined for ten years, Recbio is going to reap the rewards as several products are approaching commercialization. For more information, please visit https://www.recbio.cn/. Forward-looking statements This Press Release may contain projections, estimates, forecasts, targets, opinions, prospects, results, returns and forward-looking statements with respect to the financial condition, results of operations, capital position, strategy and business of the Group which can be identified by the use of forward-looking terminology such as "may", "will", "should", "expect", "anticipate", "project", "plan", "estimate", "seek", "intend", "target", "believe", "potential" and "reasonably possible" or the negatives thereof or other variations thereon or comparable terminology (collectively, "forward-looking statements"), including the strategic priorities, research and development projects, and any financial, investment and capital targets and any other targets, commitments and ambitions described in writing or verbally herein. Any such forward-looking statements are not a reliable indicator of future performance, as they may involve significant stated or implied assumptions and subjective judgements which may or may not prove to be correct, accurate or complete. There can be no assurance that any of the matters set out in the forward-looking statements are attainable, will actually occur or will be realised or are complete or accurate. The assumptions and judgments may prove to be incorrect, inaccurate or incomplete, and involve known and unknown risks, uncertainties, contingencies and other important actors, many of which are outside the control of the Group. There is also no assurance that the Group may develop or market its core products or other pipeline candidates successfully. Actual achievements, results, performance or other future events or conditions may differ materially from those stated, implied and/or reflected in any forward-looking statements due to a variety of risks, uncertainties and other factors (including without limitation general market conditions, regulatory changes, geopolitical tensions or data limitations and changes). Any such forward-looking statements are based on the beliefs, expectations and opinions of the Group at the date the statements are made, and the Group does not assume, and hereby disclaims, any obligation or duty to update, revise or supplement them if circumstances or management's beliefs,  expectations or opinions should change. For these reasons, you should not place reliance on, and are expressly cautioned about relying on, any forward-looking statements. No representations or warranties, expressed or implied, are given by  or on behalf of the Group as to the achievement or reasonableness of any projections, estimates, forecasts, targets, commitments, prospects or returns contained herein. Please refer to the announcements published by the Company on the websites of The Stock Exchange of Hong Kong Limited (www.hkexnew.hk) or of the Company (www.recbio.cn) for further details. If there is any inconsistency between this Presentation and the announcements, the announcements shall prevail. Jiangsu Recbio Technology Co., Ltd.Investor Inquiry:Email: ir@recbio.cnTel: +86-0523-86818860 Media Inquiry:Email: media@recbio.cnTel: +86-0523-86818860 Related Links:https://www.recbio.cn/ 

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 400 加入收藏 :
Angel Group's First Industrialized Strain of Probiotics Anchors Strategic Transformation Towards Biotechnology

YICHANG, China, Sept. 19, 2023 /PRNewswire/ -- Angel Group ("Angel") is a prominent company in the field of biotechnology, driving progress and innovation in sectors like bio-agriculture and bio-healthcare. Recently, Angel successfully achieved large-scale production of the Dangxiong LB VIII probiotics strain, a significant breakthrough that marks a milestone in Angel's strategic transformation from yeast towards biotechnology. The DB-8 hails from Dangxiong, which is at an altitude of 4,500 meters where there are towering snow mountains and vast grasslands. This edible probiotic strain belongs to Lactobacillus delbrueckii subsp. Lactis, and at its core Angel has brought its first self-developed yogurt starter culture Yo-Fru1. Angel's R&D team regularly visited Tibet and collected over 100 precious samples of plateau probiotics from more than 20 counties and townships across five cities and one district, and continually expands its Qinghai Tibet Plateau Probiotic Bank, which is the main driving force for tackling the bottleneck of plateau probiotics development. Collecting the probiotic strains is only the first step – strain isolation, identification, security evaluation, and selecting the best is a complex task.  Accordingly, Angel has expanded the R&D team and acquired advanced equipment to find the best probiotics strain and develop Yo-Fru1. DB-8 has the advantages of acid production and natural fruit aroma in its metabolites, which makes it perfect for Angel to develop differentiated yogurt products. In the process of industrializing the DB-8 in product application, Angel repeatedly experimented to elevate the taste, flavor, texture, formula cleaning and more, sought professional advice, and acquired accurate guidance in terms of raw material ratio, process optimization, and online trial production. Angel's corporate spirit of "pursuing excellence, innovation, and keep improving" has ceaselessly pushed the company to establish an integrated layout of biotechnology across the fields of food and health, biomedicine, bio-agriculture, and biomaterials. "Angel is evolving from a leader in yeast production to becoming a global innovative enterprise of biotechnology, the strategic transformation not only brings challenges but also tremendous opportunities," said Xiong Tao, president of Angel group. "With a vision of 'Developing Biotechnology, Innovate for Healthy Life,' Angel aspires to become the world's leading biotech enterprise." Angel is also leveraging the advantaged resources to promote international development, and it has invested and built factories globally and set up subsidiaries in U.S., Germany, Singapore, and Mexico to achieve localization and expand its presence in overseas markets.

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 192 加入收藏 :
首 頁 我的收藏 搜 尋 新聞發佈